JPRN-UMIN000042750尚未招募未知
Efficacy of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma - Efficacy of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Gifu university first Dept of internalmedicine0 个研究点目标入组 300 人开始时间: 2020年12月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1Untreated or incompletely treated esophageal or gastric varices.2With bleeding or high risk of bleeding.3Thromboembolic event.4Wounded.5Brain metastasis.6Uncontrolled Hypertension. 7Uncontrolled Ascites. 8History of autoimmune disease. 9Pulmonary fibrosis. 10Tuberculosis. 11Severe Hart failure. 12Long QT Syndrome. 13infection within 4weeks. 14Vaccination within 4weeks. 15Pregnant. 16Allergic. 17Un suitable Patient.
研究者
相似试验
已完成
2 期
A Phase II Study of Atezolizumab with Bevacizumab for Patients with Non-Small Cell Non-Squamous Cell Lung Cancer (At Be Study) (Investigator-Initiated Clinical Trial)non-small-cell lung cancerJPRN-jRCT2080223980Takashi Seto (Coordinating Investigator)38
已完成
Unknown
Biomarker study of Atezolizumab plus Bevacizumab for PD-L1 High Non-Sq NSCLCnon-small-cell lung cancerJPRN-jRCT1080224072Kaname Nosaki (Principal Investigator)38
进行中（未招募）
2 期
Atezo+Bev study for pretreated patientshepatocellular carcinomaJPRN-jRCT1041200068Yamashita Tatsuya28
进行中（未招募）
1 期
Evaluation of treatment combination Atezolizumab/Bevacizumab +/- Chemotherapy in patients with recurrent ovarian cancerEfficacy of atezolizumab in combination with non-platinum based chemotherapy and bevacizumab versus the combination of a non-platinum based chemotherapy and bevacizumab in recurrent ovarian cancerMedDRA version: 27.0Level: PTClassification code 10016182Term: Fallopian tube cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 27.0Level: PTClassification code 10057529Term: Ovarian cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000202-37-LTAGO Research GmbH550
进行中（未招募）
1 期
Evaluation of treatment combination Atezolizumab/Bevacizumab +/- Chemotherapy in patients with recurrent ovarian cancerEUCTR2017-000202-37-NOAGO Research GmbH664